The Heart Biomarker Evaluation in Apnea Treatment (HeartBEAT) is a multi-center Phase II randomized controlled trial that evaluates the effects of supplemental nocturnal oxygen or Positive Airway Pressure (PAP) therapy, compared to optimal medical preventive therapy, over a 3 month intervention period in patients with cardiovascular disease (CVD) or CVD risk factors and moderate to severe obstructive sleep apnea (Apnea-Hypopnea Index 15 to 50). The study's primary outcome is 24 hour blood pressure profile.
Read more about HeartBEAT at ClinicalTrials.gov (NCT01086800).
When using this dataset, please cite the following:
Zhang GQ, Cui L, Mueller R, Tao S, Kim M, Rueschman M, Mariani S, Mobley D, Redline S. The National Sleep Research Resource: towards a sleep data commons. J Am Med Inform Assoc. 2018 Oct 1;25(10):1351-1358. doi: 10.1093/jamia/ocy064. PMID: 29860441; PMCID: PMC6188513.
Gottlieb DJ, Punjabi NM, Mehra R, Patel SR, Quan SF, Babineau DC, Tracy RP, Rueschman M, Blumenthal RS, Lewis EF, Bhatt DL, Redline S. CPAP versus oxygen in obstructive sleep apnea. N Engl J Med. 2014 Jun 12;370(24):2276-85. doi: 10.1056/NEJMoa1306766. PMID: 24918372; PMCID: PMC4172401.
Please include the following text in the Acknowledgements:
The Heart Biomarker Evaluation in Apnea Treatment (HeartBEAT) study was supported by grants from the National Heart, Lung, and Blood Institute (RC2 HL101417, 1R01HL109493, R21HL108226) and National Center for Research Resources (UL1 RR024989). The National Sleep Research Resource was supported by the National Heart, Lung, and Blood Institute (R24 HL114473, 75N92019R002).